PF-07321332 Supply Agreement for Pandemic Purposes

CPV: Pharmaceutical products

Procedure method

Award procedure without prior publication of a call for competition

Legal basis

CELEX · 32014L0024 Public Contracts Regulations 2015 (Directive 2014/24/EU)

Procurement category

Goods

Notice status

Awarded without competition

Procurement threshold

Unspecified in notice

Regulatory regime

Standard

Commercial structure

Stand-alone contract (no framework)

Competition type

Direct award (no call for competition)

GPA / WTO covered

Yes (GPA)

Recurring procurement

Unspecified in notice

First published

17 Nov 2021, 18:41 GMT

Last source update

17 Nov 2021, 18:41 GMT

Authority reference

C51900

FTS notice number

2021/S 000-028748

Classification (CPV)

Pharmaceutical products

Delivery area

UK

Official registry OCID

ocds-h6vhtk-02f7bb Find a Tender

Why no open competition

The works, supplies or services can be provided only by a particular economic operator due to absence of competition for technical reasons; Extreme urgency brought about by events unforeseeable for the contracting authority/entity and in accordance with the strict conditions stated in the directive

Published justification

Regulation 32(2)(c)The procurement was initiated on the basis that Regulation 32(2)(c) was applicable. In April 2021, the Antivirals Task Force (ATF) was established as it was recognised there was an urgent to find alternative novel anti-viral treatments. As far as is strictly necessary: The use of antivirals was identified as strictly necessary for the cohort of individuals for whom a vaccine is not an option. There are genuine reasons for extreme urgency: The procurement of antivirals aims to protect vulnerable cohorts of the population. This risk of public health presents a genuine emergency.The events that have led to the need for extreme urgency were unforeseeable: There are many aspects of the COVID-19 pandemic, which have been entirely unforeseeable. DHSC is acting on the newest information it has available to tailor its COVID-19 response accordingly. The situation is not attributable to the contracting authority: The situation of extreme urgency is not attributable to DHSC.It is impossible to comply with the usual timescales in the PCR: When the need for antivirals was urgently identified in April 2021, DHSC conducted a comprehensive market review. The result of this exercise was that it became clear that a procurement exercise could not be run due to the absence of competition. If the ATF were to run a procurement process now, it would worsen DHSC’s position.Regulation 32 (2) (b) (ii)In the course of this procurement, it has become clear to DHSC that Regulation 32(2)(b)(ii) is applicable. The antivirals market is inverted, with an imbalance between demand and supply and limited worldwide supply capacity. This means there will be a finite supply of antivirals available in 2021/22: to date only two antivirals have received or have the potential to gain MHRA approval for Autumn/Winter 2021.Looking forward, DHSC is expected to publish a Prior Information Notice (PIN) in November in respect of its likely further portfolio requirements with a view to running future open procurement exercises where possible. Please see Contracts Finder Notice for full justification.

Publisher note: Information on contract value is being withheld due to commercial sensitivity under Regulation 50(6)(b) and (c) as the publication of the price may enable competitors to calculate cost per dose. This will (i) commercially prejudice the supplier in its ongoing negotiations with other national governments; (ii) commercially prejudice the contracting authority in its ongoing negotiations with other vendors and (iii) impact fair competition between vendors.

• Pfizer LimitedAwarded supplier Walton Oaks, Dorking Road, Kent, UK, KT20 7NS

No document links were published on the notice.